Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Optimal Management of Dolutegravir Resistance: an Open-label Randomised Controlled Trial of Maintaining Dolutegravir or Switch to Ritonavir-boosted Darunavir

NCT06747507 is registered in ClinicalTrials.gov with University of Nairobi as lead sponsor.

NCT NCT06747507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Optimal Management of Dolutegravir Resistance: an Open-label Randomised Controlled Trial of Maintaining Dolutegravir or Switch to Ritonavir-boosted Darunavir
Lead sponsor
University of Nairobi
Phase
Phase 3
Overall status
Recruiting
Start date
September 1, 2025
Completion date
July 31, 2027
Enrollment
392 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection